A Phase 2a Open-label Study to Investigate Safety and Tolerability (Including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination With Lenalidomide in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 21 Nov 2019
Price : $35 *
At a glance
- Drugs Lenalidomide (Primary) ; MT 3724 (Primary)
- Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Molecular Templates
- 21 Nov 2019 According to an Molecular Templates media release, the company announces pricing of $50.0 million public equity offering. The company expects to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund this ongoing study.
- 06 Nov 2019 Results assessing Safety and Tolerability of MT-3724 in Combination with Lenalidomide in patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma released at the 61st Annual Meeting and Exposition of the American Society of Hematology
- 12 Aug 2019 According to a Molecular Templates media release, data from this study is expected in the fourth quarter of 2019.